PROTOX, a subsidiary of DSK, announced on December 1 that it has signed an exclusive 10-year supply agreement with the Spanish aesthetics company Mesoestetic. The contract covers the supply of PROTOX’s independently developed botulinum toxin product.

Mesoestetic is already well known in Korea as a supplier of various aesthetic medical products. The company recorded €82.1 million in sales last year and has built a strong global network across more than 90 countries, including Europe, the United States, and Latin America.

PROTOX currently holds 23 intellectual property rights in Korea and abroad and is in the process of filing additional patents in the United States, Europe, China, and Japan. Leveraging this technological competitiveness, the company has already entered into long-term supply agreements (LTAs) with key partners in Russia (CIS), Brazil, China, and Türkiye. It is also actively engaging with leading partners in major regions such as Europe, the U.S., Latin America, the Middle East, and Southeast Asia to further expand its global presence.

A DSK official commented, “Through this contract, PROTOX has gained a foothold to advance into the European market. The company will continue expanding its global network to enhance its market reach.”